SEP 29, 2026 · JOURNAL ARTICLE
PET-derived metabolic–immunonutritional SUVmax–lactate dehydrogenase–albumin–lymphocyte index for survival prediction in human epidermal growth factor receptor 2-positive metastatic breast cancer receiving pertuzumab-based therapy
Nuclear Medicine Communications
OBJECTIVE: To evaluate the prognostic value of the PET-derived SUVmax-lactate dehydrogenase-albumin-lymphocyte (SUV-LAL) index in human epidermal growth factor receptor 2 (HER2)-po